Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Ltd has announced a change in the substantial holding of its shares, with Mitsubishi UFJ Financial Group, Inc. increasing its voting power from 5.01% to 6.08%. This change in shareholding could impact the company’s governance and strategic decisions, potentially influencing its market position and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Average Trading Volume: 922,127
Technical Sentiment Signal: Sell
Current Market Cap: A$538.1M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.